These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2015730)

  • 1. Salivary analysis for determination of dextromethorphan metabolic phenotype.
    Hou ZY; Pickle LW; Meyer PS; Woosley RL
    Clin Pharmacol Ther; 1991 Apr; 49(4):410-9. PubMed ID: 2015730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity.
    Hu OY; Tang HS; Lane HY; Chang WH; Hu TM
    J Pharmacol Exp Ther; 1998 Jun; 285(3):955-60. PubMed ID: 9618394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.
    Schmid B; Bircher J; Preisig R; Küpfer A
    Clin Pharmacol Ther; 1985 Dec; 38(6):618-24. PubMed ID: 4064464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of dextromethorphan oxidation in South Indian subjects.
    Mamidi RN; Satyavageeswaran S; Vakkalanka SV; Chaluvadi MR; Katneni K; Brahmadevara N; Damodarram G; Subramaniam S
    Clin Pharmacol Ther; 1999 Aug; 66(2):193-200. PubMed ID: 10460073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of dextromethorphan metabolizer phenotype in healthy volunteers.
    Hildebrand M; Seifert W; Reichenberger A
    Eur J Clin Pharmacol; 1989; 36(3):315-8. PubMed ID: 2744072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of dextromethorphan metabolic phenotype by salivary analysis with a reference to genotype in Chinese patients receiving renal hemodialysis.
    Hou ZY; Chen CP; Yang WC; Lai MD; Buchert ET; Chung HM; Pickle LW; Woosley RL
    Clin Pharmacol Ther; 1996 Apr; 59(4):411-7. PubMed ID: 8612385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism of dextromethorphan oxidation in a French population.
    Larrey D; Amouyal G; Tinel M; Letteron P; Berson A; Labbe G; Pessayre D
    Br J Clin Pharmacol; 1987 Nov; 24(5):676-9. PubMed ID: 3435696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
    Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
    Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation.
    Lutz U; Völkel W; Lutz RW; Lutz WK
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Dec; 813(1-2):217-25. PubMed ID: 15556536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.
    Basci NE; Bozkurt A; Kayaalp SO; Sayal A; Isimer A
    Eur J Drug Metab Pharmacokinet; 1998; 23(1):1-5. PubMed ID: 9625265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 phenotyping with dextromethorphan.
    Wojtczak A; Rychlik-Sych M; Krochmalska-Ulacha E; Skretkowicz J
    Pharmacol Rep; 2007; 59(6):734-8. PubMed ID: 18195464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation.
    Irshaid YM; al-Hadidi HF; Latif A; Awwadi F; al-Zoubi M; Rawashdeh NM
    Eur J Drug Metab Pharmacokinet; 1996; 21(4):301-7. PubMed ID: 9074894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population.
    Nagai N; Kawakubo T; Kaneko F; Ishii M; Shinohara R; Saito Y; Shimamura H; Ohnishi A; Ogata H
    Biopharm Drug Dispos; 1996 Jul; 17(5):421-33. PubMed ID: 8830977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of terbinafine as a CYP2D6 inhibitor in vivo.
    Abdel-Rahman SM; Gotschall RR; Kauffman RE; Leeder JS; Kearns GL
    Clin Pharmacol Ther; 1999 May; 65(5):465-72. PubMed ID: 10340911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P-450IID6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes.
    Anthony LB; Boeve TJ; Hande KR
    Cancer Chemother Pharmacol; 1995; 36(2):125-8. PubMed ID: 7767948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
    Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
    Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-point plasma or urine dextromethorphan method for determining CYP3A activity.
    Kuo BP; Hu OY; Hsiong CH; Pao LH; Chen TS; Hung CF
    Biopharm Drug Dispos; 2003 Dec; 24(9):367-73. PubMed ID: 14689465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of dextromethorphan O-demethylation in man.
    Küpfer A; Schmid B; Pfaff G
    Xenobiotica; 1986 May; 16(5):421-33. PubMed ID: 3739367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rapid thin layer chromatographic procedure to identify poor and extensive oxidative drug metabolizers in man using dextromethorphan.
    De Zeeuw RA; Eikema D; Franke JP; Jonkman JH
    Pharmazie; 1992 May; 47(5):346-8. PubMed ID: 1409826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dextromethorphan metabolic phenotyping in an Iranian population.
    Afshar M; Rouini M; Ala S
    Eur J Clin Pharmacol; 2005 Feb; 60(12):849-54. PubMed ID: 15657780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.